Science: In 2022, the U.S. National Institutes of Health (NIH) placed a large bet on an experimental drug developed to limit brain damage after strokes. The agency committed up to $30 million to administer a compound called 3K3A-APC in a study of 1400 people shortly after they experience an acute ischemic stroke, a perilous condition in which a clot blocks blood flow to part of the brain.
The gamble seemed warranted. Lab studies, most by a longtime grantee, prominent University of Southern California (USC) neuroscientist Berislav Zlokovic, had generated promising data. A small safety study of the drug, sponsored by a company Zlokovic co-founded called ZZ Biotech, was also encouraging. Analyses of data from the phase 2 trial hinted that the treatment reduced the number of tiny, asymptomatic brain hemorrhages after stroke patients received either surgery to remove the clot, the clot-busting drug tissue plasminogen activator (tPA), or both.
But a 113-page dossier obtained by Science from a small group of whistleblowers paints a less encouraging picture. more
I worked for a pharma company 15+ years ago. We had a chemo drug in Phase III trials when I started, then we filed with FDA for approval. One of our key, highly-paid employees had a doctorate in statistics. Because twisting the numbers is always a key part of selling the approval, especially when your drug’s efficacy may be suspect.
In our case the drug was pretty decent, a better version of one already on the market (our Abraxane had much lower side effects than Taxol, enabling a higher dosage). But we still had the statistical magician.
statistics don’t lie, statisticians do.
Didn’t you just post about….
the fast talking man, alzheimer’s, and myelin….
a few days ago….???? Like don’t f with your cholesterol with statins.
https://www.bitchute.com/video/JrY72a7wxNDr/